Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | CA1 | P00915 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | HPGDS | O60760 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 4/20 | 0.57 |
| ▸ | ACE | P12821 | 4/20 | 0.57 |
| ▸ | CPA1 | P15085 | 3/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497780 | 0.93 | PTPN1 (0.72) | CA2CA1PTPN1HPGDSCTSL | |
| SCHEMBL8520566 | 0.93 | PTPN1 (0.72) | CA2CA1PTPN1HPGDSCTSL | |
| SCHEMBL3404637 | 0.93 | CA2 (0.69) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL8667639 | 0.93 | CA2 (0.69) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL5793343 | 0.93 | CA2 (0.69) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL8671997 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL4054764 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL4054766 | 0.93 | CA2 (0.77) | CA2CA1PTPN1CTSLCA12 | |
| SCHEMBL10033681 | 0.91 | PTPN1 (0.69) | CA2CA1PTPN1ITGB1ITGA4 | |
| SCHEMBL6857183 | 0.91 | PTPN1 (0.69) | CA2CA1PTPN1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215598-A1 | Phenylalanine derivatives | CELLTECH R&D LTD. (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1056714-B1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166691-A1 | Phenylalanine derivatives | ARCHIBALD SARAH CATHERINE (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6555562-B1 | 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders | CELLTECH R&D LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
| EP-1056714-A1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043642-A1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166691-A1 | Phenylalanine derivatives | VCAM1, PAH, ITGB4 | CA2 2829/4885CA1 3242/4885PTPN1 492/4885 |
| US-20050215598-A1 | Phenylalanine derivatives | PAH, ITGB4, VCAM1 | CA2 2980/4885CA1 3032/4885PTPN1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.